Aug 09 2024 This Week in Cardiology

This Week in Cardiology

Prediction models vs clinical judgement, CCTA quantification of atherosclerosis, AF ablation plus LAAO, atrial shunt devices, and HF medical therapy are topics John Mandrola, MD, covers this week.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I.Clinical Prediction Models vs Clinical Judgement

Did Statin Decision-Making Just Get Harder?

https://www.medscape.com/viewarticle/did-statin-decision-making-just-get-harder-2024a1000egl

• Colunga-Lozano and colleagues
• https://doi.org/10.1016/j.jclinepi.2023.10.016
• Aug 02, 2024 This Week in Cardiology Podcast
• https://www.medscape.com/viewarticle/1001429

II. CCTA Quantification of Atherosclerosis

• Atherosclerosis Quantification and Cardiovascular Risk: the ISCHEMIA Trial https://doi.org/10.1093/eurheartj/ehae471
• Circulation ISCHEMIA sub study 2021 – Severity of CAD and Outcomes https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.049755
• ISCHEMIA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1915922

III. Combined AF Ablation and LAAO

• Review from Mills and colleagues https://doi.org/10.1016/j.tcm.2023.11.003
• Link to CMS Rule on AF Ablation and LAAO https://hrs2.informz.net/z/cjUucD9taT05MjU3ODgyJnA9MSZ1PTkwMDQ2MTk4MCZsaT04NTU1OTQxMg/index.html

IV. Atrial Shunt Devices

No Net HF Benefit for Interatrial Shunt Device

https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk

• Original REDUCE-LAP-HF-II https://doi.org/10.1016/S0140-6736(22)00016-2
• Two-year results of REDUCE-LAP-HF-II https://doi.org/10.1016/j.jchf.2024.04.011
• Apr 19, 2024 This Week in Cardiology Podcast

V. Optimal HF Therapy

• Rao and colleagues; CHAMP HF https://doi.org/10.1016/j.jchf.2024.05.026

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [e-mail]